Depletion of cardiac cardiolipin synthase alters systolic and diastolic function
Elia Smeir,
Sarah Leberer,
Annelie Blumrich,
Georg Vogler,
Anastasia Vasiliades,
Sandra Dresen,
Carsten Jaeger,
Yoann Gloaguen,
Christian Klose,
Dieter Beule,
P. Christian Schulze,
Rolf Bodmer,
Anna Foryst-Ludwig,
Ulrich Kintscher
Affiliations
Elia Smeir
Charite - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health/ Institute of Pharmacology, Center for Cardiovascular Research, Hessische Street 3-4, 10115 Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site, Berlin, Germany
Sarah Leberer
Charite - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health/ Institute of Pharmacology, Center for Cardiovascular Research, Hessische Street 3-4, 10115 Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site, Berlin, Germany
Annelie Blumrich
Charite - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health/ Institute of Pharmacology, Center for Cardiovascular Research, Hessische Street 3-4, 10115 Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site, Berlin, Germany
Georg Vogler
Development, Aging and Regeneration Program, Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA 92037, USA
Anastasia Vasiliades
Charite - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health/ Institute of Pharmacology, Center for Cardiovascular Research, Hessische Street 3-4, 10115 Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site, Berlin, Germany
Sandra Dresen
Charite - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health/ Institute of Pharmacology, Center for Cardiovascular Research, Hessische Street 3-4, 10115 Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site, Berlin, Germany
Carsten Jaeger
Federal Institute for Materials Research and Testing (BAM), Berlin, Germany
Yoann Gloaguen
Berlin Institute of Health, BIH, Core Unit Bioinformatics, Berlin, Germany; Berlin Institute of Health, BIH, Metabolomics Platform, Berlin, Germany
Christian Klose
Lipotype GmbH, Dresden, Germany
Dieter Beule
Berlin Institute of Health, BIH, Core Unit Bioinformatics, Berlin, Germany
P. Christian Schulze
Department of Internal Medicine I, Division of Cardiology, Angiology, Pneumology and Intensive Medical Care, University Hospital Jena, Friedrich-Schiller-University Jena, Jena, Germany
Rolf Bodmer
Development, Aging and Regeneration Program, Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA 92037, USA
Anna Foryst-Ludwig
Charite - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health/ Institute of Pharmacology, Center for Cardiovascular Research, Hessische Street 3-4, 10115 Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site, Berlin, Germany
Ulrich Kintscher
Charite - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health/ Institute of Pharmacology, Center for Cardiovascular Research, Hessische Street 3-4, 10115 Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site, Berlin, Germany; Corresponding author
Summary: Cardiolipin (CL) is a major cardiac mitochondrial phospholipid maintaining regular mitochondrial morphology and function in cardiomyocytes. Cardiac CL production includes its biosynthesis and a CL remodeling process. Here we studied the impact of CL biosynthesis and the enzyme cardiolipin synthase (CLS) on cardiac function. CLS and cardiac CL species were significantly downregulated in cardiomyocytes following catecholamine-induced cardiac damage in mice, accompanied by increased oxygen consumption rates, signs of oxidative stress, and mitochondrial uncoupling. RNAi-mediated cardiomyocyte-specific knockdown of CLS in Drosophila melanogaster resulted in marked cardiac dilatation, severe impairment of systolic performance, and slower diastolic filling velocity assessed by fluorescence-based heart imaging. Finally, we showed that CL72:8 is significantly decreased in cardiac samples from patients with heart failure with reduced ejection fraction (HFrEF). In summary, we identified CLS as a regulator of cardiac function. Considering the cardiac depletion of CL species in HFrEF, pharmacological targeting of CLS may be a promising therapeutic approach.